At WSJ Journal House in Davos, Albert Bourla describes how discussions with the U.S. Secretary of Health and Human Services ...

Robert F. Kennedy’s position on vaccines is profoundly "anti-science" and making progress would require a new health secretary, Pfizer Chief Executive Albert Bourla said Wednesday. “I have very ...

Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...

Albert Bourla, CEO of Pfizer, joins 'Money Movers' to discuss drug pricing, the impact on artificial intelligence on ...

We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...